Glucagon and GLP-1 receptor co-agonist
Cotadutide 200 ug subcutaneous once daily
COTA_SC_200UG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.80 (-1.30 to -0.30) | 0.44 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.61 (-0.90 to -0.32) | 0.81 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.80 (-3.53 to 0.26) | 0.59 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.23 (-3.85 to -0.62) | 0.77 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 3.88 (1.55 to 8.70) | 0.49 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -2.60 (-7.09 to 3.01) | 0.55 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -1.71 (-7.91 to 5.93) | 0.52 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.71 (0.74 to 7.28) | 0.43 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 3.52 (1.00 to 9.40) | 0.46 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 6.86 (1.44 to 36.34) | 0.60 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.31 (0.74 to 2.36) | 0.35 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 5.79 (2.54 to 13.45) | 0.15 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.65 (3.24 to 9.97) | 0.21 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 9.21 (4.50 to 20.77) | 0.14 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.94 (2.60 to 9.66) | 0.10 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.66 (0.94 to 8.36) | 0.32 |